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Living Up to the PROMISEIs There an Ultimate Winner?We read with great interest the review by Marwick
et al. (1) discussing the potential role of coronary
computed tomography angiography (CCTA) in the
current paradigm of chest pain evaluation following
the PROMISE (Prospective Multicenter Imaging Study
for Evaluation of Chest Pain) trial. On the basis of
the existing evidence, the authors argue that CCTA
can serve as an effective gatekeeper to invasive
angiography. The PROMISE trial is interpreted by
many as an “equivocal” study without any obvious
“winner” because neither of the testing strategies
(anatomic vs. physiological) resulted in improved
outcome. But are there any advantages that would
favor any particular modality? We strongly argue thatstress echocardiography emerged as the ultimate
“winner.”
It is well known that the negative predictive value of
CCTA for coronary disease in low- and low-
intermediate-risk patients is high. But the clinically
meaningful outcome beneﬁt of CCTA versus phy-
siological modalities has not yet been convincingly
demonstrated. On the other hand, CCTA is associ-
ated with contrast and radiation exposure in these
younger patients. Low-dose radiation–related risks
have been recently conﬁrmed by both a longitudinal
study and protein and genetic biomarker changes (2).
Stress echocardiography is efﬁcient, inexpensive, and
safe. In the PROMISE trial, the cumulative radiation
exposure up to 90 days after randomization was
markedly lower among patients undergoing stress
echocardiography as compared with CCTA (1.3 vs.
12.6 mSv; p < 0.001) (1,3). Moreover, in younger
patients, noncoronary causes of chest symptoms
(such as hypertrophic cardiomyopathy with latent
obstruction, valve disease, and pulmonary hyper-
tension) are relatively common, and these can be
properly evaluated by stress echocardiography.
Finally, incidental noncardiac ﬁndings on CCTA may
provoke unnecessary anxiety and lead to further
testing.
In high-risk (older) patients with a higher preva-
lence of coronary disease, CCTA results in “incidental”
coronary ﬁndings, as described by Marwick et al. (1).
The main advantage of stress echocardiography
in these settings is correlation of stress test
ﬁndings with patient symptoms, because routine
revascularization in stable coronary disease offers
no outcome beneﬁt. A prior ﬁnding of higher
revascularization rates with CCTA compared with
patients undergoing physiological testing was
conﬁrmed in the PROMISE trial (6.2% vs. 3.2% within
90 days; p < 0.001) (4).
In the current stage, with rapidly increasing
options for noninvasive imaging, one should make
an argument that a modality with the best balance
of versatility, accuracy, safety, and cost effectiveness
should prevail. The accumulating evidence so far
argues in favor of stress echocardiography.*Vikram Agarwal, MD, MPH
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